Gyre Therapeutics, Inc. (NASDAQ:GYRE) Sees a 14.4% Increase in Short Interest for December

Gyre Therapeutics, Inc. (NASDAQ:GYRE) experienced a noteworthy rise in short interest during December. On December 31st, the total short interest reached 952,300 shares, marking a 14.4% increase from the 832,200 shares reported on December 15th. Currently, about 4.4% of the company's shares are sold short. With an average daily trading volume of 94,200 shares, the short-interest ratio stands at 10.1 days.

Insider Transactions at Gyre Therapeutics

In additional news regarding Gyre Therapeutics, President Songjiang Ma sold 2,000 shares of the company's stock on December 26th. The shares were sold at an average price of $12.70, totaling $25,400. Following this sale, President Ma holds 2,928,467 shares of Gyre Therapeutics, valued at approximately $37,191,530.90, indicating a 0.07% decrease in personal ownership of the stock. This transaction was recorded in a filing with the SEC. Over the past 90 days, insiders have sold a total of 16,054 shares valued at $185,897, with 19.52% of the company owned by insiders.

Changes in Institutional Ownership

Recent trading activity has seen several large investors trade shares of Gyre Therapeutics. For instance, Charles Schwab Investment Management Inc. increased its stake by 392.2% during the third quarter, now holding 113,648 shares worth $1,425,000 after acquiring an additional 90,557 shares. Geode Capital Management LLC also increased its holdings by 16.9% in the same period, owning 303,647 shares now worth $3,808,000 after a purchase of 43,840 shares. Other institutional movements include Advantage Alpha Capital Partners LP and Bank of New York Mellon Corp acquiring new stakes valued at approximately $334,000 and $218,000 respectively. Collectively, institutional investors and hedge funds possess 23.99% of Gyre Therapeutics' stock.

Recent Trading Activity

On Friday, Gyre Therapeutics saw its stock rise by 1.4%, trading up $0.15 to reach $10.95. The trading volume for the day was 48,956 shares, below the average volume of 116,811 shares. The stock has a 50-day moving average of $11.57 and a 200-day moving average of $12.64, with a 1-year low of $8.26 and a 1-year high of $26.37.

About Gyre Therapeutics

Gyre Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing Hydronidone to treat Metabolic Dysfunction Associated Steatohepatitis in the United States. Additionally, Hydronidone is under evaluation for treating liver fibrosis in various chronic liver diseases.

Gyre, Therapeutics, Short